Equities Analysts Offer Predictions for KALV Q4 Earnings
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Free Report) – Investment analysts at Leerink Partnrs issued their Q4 2025 EPS estimates for KalVista Pharmaceuticals in a report issued on Tuesday, March 25th. Leerink Partnrs analyst J. Schwartz forecasts that the specialty pharmaceutical company will post earnings per share of ($0.77) for the quarter. The consensus estimate for […]
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Free Report) – Investment analysts at Leerink Partnrs issued their Q4 2025 EPS estimates for KalVista Pharmaceuticals in a report issued on Tuesday, March 25th. Leerink Partnrs analyst J. Schwartz forecasts that the specialty pharmaceutical company will post earnings per share of ($0.77) for the quarter. The consensus estimate for […]
